{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/GILD/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-23T07:59:41.436Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":8383,"canonical_name":"GILEAD SCIENCES, INC.","cik":"0000882095","uei":null,"lei":null,"duns":null,"ticker":"GILD"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":51,"clinical":20,"open":1,"dol":1},"count":73,"timeline":[{"ts":"2026-09-10","kind":"sec.insider.f","reporter":"O'Day Daniel Patrick","title":"Chairman & CEO","shares":4230,"price_per_share":144.81,"usd_value":612546,"security_title":"Common Stock","importance":15.6125463},{"ts":"2026-09-10","kind":"sec.insider.f","reporter":"Dickinson Andrew D","title":"Chief Financial Officer","shares":1347,"price_per_share":144.81,"usd_value":195059,"security_title":"Common Stock","importance":15.19505907},{"ts":"2026-09-10","kind":"sec.insider.f","reporter":"Mercier Johanna","title":"Chief Comm & Corp Aff Officer","shares":1347,"price_per_share":144.81,"usd_value":195059,"security_title":"Common Stock","importance":15.19505907},{"ts":"2026-09-10","kind":"sec.insider.f","reporter":"Cain Wettan Keeley M","title":"EVP Gen Counsel,  Legal & Comp","shares":285,"price_per_share":144.81,"usd_value":41271,"security_title":"Common Stock","importance":15.04127085},{"ts":"2026-09-10","kind":"sec.insider.f","reporter":"Berger Dietmar","title":"Chief Medical Officer","shares":263,"price_per_share":144.81,"usd_value":38085,"security_title":"Common Stock","importance":15.03808503},{"ts":"2026-09-10","kind":"sec.insider.m","reporter":"Dickinson Andrew D","title":"Chief Financial Officer","shares":2797,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-09-10","kind":"sec.insider.m","reporter":"O'Day Daniel Patrick","title":"Chairman & CEO","shares":8780,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-09-10","kind":"sec.insider.m","reporter":"Berger Dietmar","title":"Chief Medical Officer","shares":533,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-09-10","kind":"sec.insider.m","reporter":"Mercier Johanna","title":"Chief Comm & Corp Aff Officer","shares":2797,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-09-10","kind":"sec.insider.m","reporter":"Cain Wettan Keeley M","title":"EVP Gen Counsel,  Legal & Comp","shares":590,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-08-10","kind":"sec.insider.f","reporter":"Cain Wettan Keeley M","title":"EVP Gen Counsel,  Legal & Comp","shares":2908,"price_per_share":133.06,"usd_value":386938,"security_title":"Common Stock","importance":15.38693848},{"ts":"2026-08-10","kind":"sec.insider.m","reporter":"Cain Wettan Keeley M","title":"EVP Gen Counsel,  Legal & Comp","shares":6002,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-15","kind":"sec.form144","reporter":"ANDREW DICKINSON","title":"Officer","shares":3000,"usd_value":389777,"security_title":"Common","approx_sale_date":"2026-07-15","accession_number":"0001950047-26-007091","importance":40.07795536},{"ts":"2026-07-15","kind":"sec.form144","reporter":"JOHANNA MERCIER","title":"Officer","shares":3000,"usd_value":389758,"security_title":"Common","approx_sale_date":"2026-07-15","accession_number":"0001950047-26-007094","importance":40.07795152},{"ts":"2026-07-15","kind":"sec.insider.s","reporter":"Dickinson Andrew D","title":"Chief Financial Officer","shares":3000,"price_per_share":129.9256,"usd_value":389777,"security_title":"Common Stock","importance":35.3897768},{"ts":"2026-07-15","kind":"sec.insider.s","reporter":"Mercier Johanna","title":"Chief Comm & Corp Aff Officer","shares":3000,"price_per_share":129.9192,"usd_value":389758,"security_title":"Common Stock","importance":35.3897576},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"O'Day Daniel Patrick","title":"Chairman & CEO","shares":11900,"price_per_share":126.0897,"usd_value":1500467,"security_title":"Common Stock","importance":36.50046743},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"O'Day Daniel Patrick","title":"Chairman & CEO","shares":3100,"price_per_share":127.075,"usd_value":393933,"security_title":"Common Stock","importance":35.3939325},{"ts":"2026-06-15","kind":"sec.form144","reporter":"ANDREW DICKINSON","title":"Officer","shares":3000,"usd_value":376200,"security_title":"Common","approx_sale_date":"2026-06-15","accession_number":"0001950047-26-006086","importance":40.07524},{"ts":"2026-06-15","kind":"sec.form144","reporter":"JOHANNA MERCIER","title":"Officer","shares":3000,"usd_value":371762,"security_title":"Common","approx_sale_date":"2026-06-15","accession_number":"0001950047-26-006066","importance":40.07435242},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"Dickinson Andrew D","title":"Chief Financial Officer","shares":3000,"price_per_share":125.4,"usd_value":376200,"security_title":"Common Stock","importance":35.3762},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"Mercier Johanna","title":"Chief Comm & Corp Aff Officer","shares":1480,"price_per_share":123.4166,"usd_value":182657,"security_title":"Common Stock","importance":35.182656568},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"Mercier Johanna","title":"Chief Comm & Corp Aff Officer","shares":1070,"price_per_share":123.9958,"usd_value":132676,"security_title":"Common Stock","importance":35.132675506},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"Mercier Johanna","title":"Chief Comm & Corp Aff Officer","shares":450,"price_per_share":125.4,"usd_value":56430,"security_title":"Common Stock","importance":35.05643},{"ts":"2026-06-11","kind":"sec.filing","form_type":"4","title":"4 — Berger Dietmar — 2026-06-11","url_slug":"/sec/cik-0001739515/4/0001739515-26-000008","accession_number":"0001739515-26-000008","importance":30},{"ts":"2026-06-10","kind":"sec.insider.f","reporter":"O'Day Daniel Patrick","title":"Chairman & CEO","shares":4213,"price_per_share":121.48,"usd_value":511795,"security_title":"Common Stock","importance":15.51179524},{"ts":"2026-06-10","kind":"sec.insider.f","reporter":"Dickinson Andrew D","title":"Chief Financial Officer","shares":1341,"price_per_share":121.48,"usd_value":162905,"security_title":"Common Stock","importance":15.16290468},{"ts":"2026-06-10","kind":"sec.insider.f","reporter":"Mercier Johanna","title":"Chief Comm & Corp Aff Officer","shares":1341,"price_per_share":121.48,"usd_value":162905,"security_title":"Common Stock","importance":15.16290468},{"ts":"2026-06-10","kind":"sec.insider.f","reporter":"Cain Wettan Keeley M","title":"EVP Gen Counsel,  Legal & Comp","shares":283,"price_per_share":121.48,"usd_value":34379,"security_title":"Common Stock","importance":15.03437884},{"ts":"2026-06-10","kind":"sec.insider.f","reporter":"Berger Dietmar","title":"Chief Medical Officer","shares":263,"price_per_share":121.48,"usd_value":31949,"security_title":"Common Stock","importance":15.03194924},{"ts":"2026-06-10","kind":"sec.insider.m","reporter":"Dickinson Andrew D","title":"Chief Financial Officer","shares":2796,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-10","kind":"sec.insider.m","reporter":"O'Day Daniel Patrick","title":"Chairman & CEO","shares":8779,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-10","kind":"sec.insider.m","reporter":"Berger Dietmar","title":"Chief Medical Officer","shares":533,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-10","kind":"sec.insider.m","reporter":"Mercier Johanna","title":"Chief Comm & Corp Aff Officer","shares":2796,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-10","kind":"sec.insider.m","reporter":"Cain Wettan Keeley M","title":"EVP Gen Counsel,  Legal & Comp","shares":589,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-01","kind":"sec.form144","reporter":"DANIEL O'DAY","title":"Director, Officer","shares":35000,"usd_value":4705050,"security_title":"Common","approx_sale_date":"2026-06-01","accession_number":"0001950047-26-005428","importance":40.94101},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"O'Day Daniel Patrick","title":"Chairman & CEO","shares":10900,"price_per_share":131.0994,"usd_value":1428983,"security_title":"Common Stock","importance":36.42898346},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"O'Day Daniel Patrick","title":"Chairman & CEO","shares":3062,"price_per_share":132.2151,"usd_value":404843,"security_title":"Common Stock","importance":35.4048426362},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"O'Day Daniel Patrick","title":"Chairman & CEO","shares":1038,"price_per_share":132.9678,"usd_value":138021,"security_title":"Common Stock","importance":35.1380205764},{"ts":"2026-05-20","kind":"sec.filing","form_type":"8-K","title":"8-K — GILEAD SCIENCES, INC. — 2026-05-20","url_slug":"/sec/cik-0000882095/8-k/0001104659-26-064518","accession_number":"0001104659-26-064518","importance":35},{"ts":"2026-05-18","kind":"sec.filing","form_type":"424B5","title":"424B5 — GILEAD SCIENCES, INC. — 2026-05-18","url_slug":"/sec/cik-0000882095/424b5/0001104659-26-063199","accession_number":"0001104659-26-063199","importance":30},{"ts":"2026-05-15","kind":"sec.form144","reporter":"JOHANNA MERCIER","title":"Officer","shares":28000,"usd_value":3676198,"security_title":"Common","approx_sale_date":"2026-05-15","accession_number":"0001950047-26-004585","importance":40.73523955},{"ts":"2026-05-15","kind":"sec.form144","reporter":"ANDREW DICKINSON","title":"Officer","shares":3000,"usd_value":396810,"security_title":"Common","approx_sale_date":"2026-05-15","accession_number":"0001950047-26-004577","importance":40.079362},{"ts":"2026-05-15","kind":"sec.insider.s","reporter":"Mercier Johanna","title":"Chief Comm & Corp Aff Officer","shares":11177,"price_per_share":131.1917,"usd_value":1466330,"security_title":"Common Stock","importance":36.4663296309},{"ts":"2026-05-15","kind":"sec.insider.s","reporter":"Mercier Johanna","title":"Chief Comm & Corp Aff Officer","shares":8374,"price_per_share":132.2324,"usd_value":1107314,"security_title":"Common Stock","importance":36.1073141176},{"ts":"2026-05-15","kind":"sec.insider.s","reporter":"Mercier Johanna","title":"Chief Comm & Corp Aff Officer","shares":7749,"price_per_share":130.2915,"usd_value":1009629,"security_title":"Common Stock","importance":36.0096288335},{"ts":"2026-05-15","kind":"sec.insider.s","reporter":"Dickinson Andrew D","title":"Chief Financial Officer","shares":3000,"price_per_share":132.27,"usd_value":396810,"security_title":"Common Stock","importance":35.39681},{"ts":"2026-05-15","kind":"sec.insider.s","reporter":"Mercier Johanna","title":"Chief Comm & Corp Aff Officer","shares":700,"price_per_share":132.7514,"usd_value":92926,"security_title":"Common Stock","importance":35.09292598},{"ts":"2026-05-15","kind":"sec.insider.m","reporter":"Mercier Johanna","title":"Chief Comm & Corp Aff Officer","shares":25000,"price_per_share":66.64,"usd_value":1666000,"security_title":"Common Stock","importance":16.666},{"ts":"2026-05-14","kind":"sec.filing","form_type":"424B5","title":"424B5 — GILEAD SCIENCES, INC. — 2026-05-14","url_slug":"/sec/cik-0000882095/424b5/0001104659-26-060745","accession_number":"0001104659-26-060745","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"FWP","title":"FWP — GILEAD SCIENCES, INC. — 2026-05-14","url_slug":"/sec/cik-0000882095/fwp/0001104659-26-061317","accession_number":"0001104659-26-061317","importance":30},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"Gilead Sciences","title":"Study of GS-3242 in Participants With HIV-1; Substudy-05","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT07001319","excerpt":"[\"HIV-1-infection\"]","importance":30},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"Gilead Sciences","title":"Study of GS-0151 in Participants With Rheumatoid Arthritis","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06902519","excerpt":"[\"Rheumatoid Arthritis\"]","importance":30},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"Gilead Sciences","title":"Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05089734","excerpt":"[\"Non-Small Cell Lung Cancer\"]","importance":60},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Gilead Sciences","title":"Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT02842086","excerpt":"[\"Pre-Exposure Prophylaxis of HIV-1 Infection\"]","importance":60},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Gilead Sciences","title":"Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT03301506","excerpt":"[\"Primary Biliary Cirrhosis\"]","importance":60},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Gilead Sciences","title":"An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT04950764","excerpt":"[\"Primary Biliary Cholangitis\",\"Compensated Cirrhosis\",\"Hepatic Impairment\"]","importance":30},{"ts":"2026-04-30","kind":"clinical.trial","reporter":"Gilead Sciences","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06630286","excerpt":"[\"HIV-1-infection\"]","importance":60},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Gilead Sciences","title":"Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06801834","excerpt":"[\"Extensive Stage Small Cell Lung Cancer (ES-SCLC)\"]","importance":60},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Gilead Sciences","title":"Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07096193","excerpt":"[\"Chronic Hepatitis Delta\"]","importance":45},{"ts":"2026-04-28","kind":"clinical.trial","reporter":"Gilead Sciences","title":"Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT03964727","excerpt":"[\"Metastatic Solid Tumor\"]","importance":45},{"ts":"2026-04-24","kind":"clinical.trial","reporter":"Gilead Sciences","title":"Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06749054","excerpt":"[\"HIV-1-infection\"]","importance":45},{"ts":"2026-04-21","kind":"clinical.trial","reporter":"Gilead Sciences","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","security_title":"PHASE2,PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT02016924","excerpt":"[\"Acquired Immune Deficiency Syndrome (AIDS)\",\"HIV Infections\"]","importance":60},{"ts":"2026-04-21","kind":"clinical.trial","reporter":"Gilead Sciences","title":"Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06532565","excerpt":"[\"Advanced Solid Tumors\"]","importance":30},{"ts":"2026-04-17","kind":"clinical.trial","reporter":"Gilead Sciences","title":"Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed","security_title":"PHASE2,PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06544733","excerpt":"[\"HIV-1-Infection\"]","importance":60},{"ts":"2026-04-16","kind":"clinical.trial","reporter":"Gilead Sciences","title":"Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06082960","excerpt":"[\"Solid Tumors\"]","importance":30},{"ts":"2026-04-15","kind":"clinical.trial","reporter":"Gilead Sciences","title":"Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated","security_title":"PHASE2,PHASE3","status":"TERMINATED","accession_number":"NCT06613685","excerpt":"Sponsor decision to terminate study.","importance":80},{"ts":"2026-04-14","kind":"clinical.trial","reporter":"Gilead Sciences","title":"Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer","security_title":"PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07527858","excerpt":"[\"Advanced Microsatellite Stable Colorectal Cancer\"]","importance":45},{"ts":"2026-04-09","kind":"clinical.trial","reporter":"Gilead Sciences","title":"Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06290934","excerpt":"[\"Ulcerative Colitis\"]","importance":45},{"ts":"2026-04-06","kind":"clinical.trial","reporter":"Gilead Sciences","title":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05382299","excerpt":"[\"Triple Negative Breast Cancer\",\"PD-L1 Negative\"]","importance":60},{"ts":"2026-03-30","kind":"clinical.trial","reporter":"Gilead Sciences","title":"Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04994509","excerpt":"[\"Pre-Exposure Prophylaxis of HIV Infection\"]","importance":60},{"ts":"2024-12-31","kind":"open.payments","reporter":"Gilead Sciences, Inc.","title":"$21888082.0 to 29912 physicians (2024–2024)","security_title":"manufacturer","excerpt":"Biktarvy","accession_number":"2024","usd_value":21888082,"importance":70},{"ts":"2024-12-31","kind":"dol.form5500","reporter":"GILEAD SCIENCES, INC.","title":"GILEAD SCIENCES 401(K) PLAN","security_title":"Pension: 2J2K2T3H2F2G3D2R","excerpt":"Total participants 15334 · plan number 001","accession_number":"20250606160409NAL0021488048001","importance":60}]}